Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129962 | 0.91 | SCN9A (0.40) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1093817 | 0.89 | SCN9A (0.62) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL16223640 | 0.86 | SCN9A (0.35) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690576 | 0.85 | SCN9A (0.56) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL319861 | 0.85 | SCN9A (0.35) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL9924690 | 0.84 | SCN9A (0.54) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690643 | 0.83 | SCN9A (0.54) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL16223588 | 0.83 | KDM4E (0.36) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1093887 | 0.83 | SCN9A (0.61) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690540 | 0.83 | SCN9A (0.51) | SCN9ACYP2C9SCN1ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109696-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | SCN9A 10/4885CYP2C9 243/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.